Data as of Jan 30
| -0.30 / -2.44%|
The 13 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 22.00, with a high estimate of 52.00 and a low estimate of 14.00. The median estimate represents a +83.33% increase from the last price of 12.00.
The current consensus among 19 polled investment analysts is to Hold stock in Sarepta Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.